IGF-1 LR3.
About IGF-1 LR3
IGF-1 LR3 is among the peptides researched in the context of the growth hormone (GH) axis. Due to its structural modifications, IGF-1 LR3 binds poorly to IGF binding proteins, allowing it to circulate longer in an unbound, receptor-active form compared to native IGF-1.
Research Application
Studied in growth-factor signaling research, since its structural modifications are intended to allow longer receptor-active availability compared to native IGF-1. Approved IGF-1 preparations exist only for a rare genetic indication.
Important to know
Claims circulating online are often not backed by valid clinical data. Treat all information as a starting point for your own scientific research, not as usage guidance.
Sequence and regulatory status data are based on publicly available sources and refer to the compound in general, not to a specific product.
Research Overview
Numerous preclinical and some clinical studies exist on the GH axis, with evidentiary strength varying by substance.
- Yoshida T, Delafontaine P. Cells. 2020;9(9):1970. PMID 32858949
- Barton-Davis ER, et al. Acta Physiol Scand. 1999;167(4):301–305. PMID 10632630
- Tomas FM, et al. J Endocrinol. 1997;155(2):377–386. PMID 9415072
References without a PMID can be located via the respective publisher. This overview does not claim to be exhaustive.
Question about IGF-1 LR3?
We reply personally – via email or Telegram.